Windlas Biotech Limited (WINDLAS)
Press Release
Press Release - Q1FY27
- Revenue 248cr +18% y-y; Adjusted EBITDA 34cr +26% y-y (margin 13.6%); Adjusted PAT 25cr +37% y-y (margin 10%)
- Generic Formulations CDMO revenue up 29% to 207cr, 84% of total
- Trade Generics revenue down 32% to 30cr due to codeine product discontinuation
- Exports revenue up 79% to 11cr, 4% of total
- Plant-6 commercialization on track for H1 FY27 to boost capacity
- Completed 47cr share buyback without promoter participation
- FY26 dividend paid Rs 6.3/share totaling 13cr
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 WINDLAS — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add WINDLAS to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Windlas Biotech Limited
Important.
The summary above is generated automatically from Windlas Biotech Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.